Medpace (NASDAQ: MEDP) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.
Analyst Recommendations
Get Medpace alerts:This is a breakdown of recent ratings and recommmendations for Medpace and Anavex Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medpace | 0 | 7 | 1 | 0 | 2.13 |
| Anavex Life Sciences | 0 | 0 | 4 | 0 | 3.00 |
Medpace presently has a consensus target price of $37.40, indicating a potential downside of 15.67%. Anavex Life Sciences has a consensus target price of $7.50, indicating a potential upside of 129.36%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Medpace.
Earnings & Valuation
This table compares Medpace and Anavex Life Sciences’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medpace | $436.15 million | 3.61 | $39.12 million | $1.52 | 29.18 |
| Anavex Life Sciences | N/A | N/A | -$13.46 million | ($0.33) | -9.91 |
Medpace has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Medpace has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Insider & Institutional Ownership
26.8% of Medpace shares are owned by institutional investors. Comparatively, 23.0% of Anavex Life Sciences shares are owned by institutional investors. 29.5% of Medpace shares are owned by insiders. Comparatively, 12.1% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Medpace and Anavex Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medpace | 10.37% | 12.50% | 7.08% |
| Anavex Life Sciences | N/A | -73.46% | -65.73% |
Summary
Medpace beats Anavex Life Sciences on 9 of the 13 factors compared between the two stocks.
Medpace Company Profile
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
No comments:
Post a Comment